A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis( KOA)
A Study to Evaluate the Safety, Tolerability and Efficacy of NCR100 Injection for the Treatment of Knee Osteoarthritis( KOA)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yanqiu Li, PHD
- Phone Number: 021-64369181
- Email: yqli@nuwacell.com
Study Contact Backup
- Name: Changqing 021-64369181, PHD
- Phone Number: 021-64369181
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects who understand and voluntarily sign the Informed Consent Form(ICF) before the enrolment;
- Age: 40-65 years old, both genders;
- Diagnosis of knee osteoarthritis based on American College of Rheumatology criteria;
- Subjects with KOA who have persistent pain for more than six months
- Kellgren-Lawrence grade: II-III
Exclusion Criteria:
- Subjects previously diagnosed of secondary knee osteoarthritis, or those diagnosed with hip/ankle joint disease requiring medical intervention;
- Suffering from other diseases that impair knee function or joints;
- Have received stem cell therapy;
- Have knee injury history;
- Experienced knee surgery, or plan to undergo knee surgery;
- Received analgesics to relieve pain before Investigational Medicinal Product(IMP) injections;
- Have used traditional Chinese medicine to treat KOA within 4 weeks;
- Have used intra-articular injection of drugs to treat KOA within 12 weeks;
- Received glucosamine,chondroitin sulfate, or diacetate therapy before investigational drug intervention within 12 weeks;
- Subjects with acute phase of knee osteoarthritis;
- Severe deformity of the knee;
- Known or suspected allergy or a history of allergies;
- Abnormal results of laboratory examination as follows: Hepatic Insufficiency (Alanine Aminotransferase>2xULN or Aspartate aminotransferase [ast]>2xULN) renal dysfunction (creatinine clearance rate ≤60ml/min or blood urea nitrogen(BUN) > 2× ULN), Coagulation Defects (INR > 1.5) or severe hematological diseases (Grade 3 or above anemia [Hb < 8 g/dL], Grade 2 or above thrombocytopenia platelet count(PLT) < 75×10^9/L) ;
- BMI≥30kg/m^2
- Severe systemic infection or local knee joint infection;
- Have received systemic glucocorticoid therapy before intervention or need to take systemic glucocorticoid therapy during the treatment;
- Have a history of acute myocardial infarction or severe heart diseases,QT prolongation;
- Subjects with peripheral or central nervous system disorders that may interfere assessments;
- Have contraindications to Magnetic Resonance Imaging(MRI)
- Subjects who are unable to walk on his own;
- Subjects with alcohol/drug addiction/abuse or mental disorders;
- Pregnant or lactating, or unable to comply with contraceptives within 6 months after end of study;
- Have participated in other clinical trials within 12 weeks before the screening;
- Severe and poorly controlled comorbidities;
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NCR100 injection
Subjects will receive four injections of NCR100
|
Subjects will receive multiple intra-articular NCR100 injections.
|
|
Placebo Comparator: 0.9% Normal saline
Subjects will receive four injections of 0.9% Normal saline
|
Subjects will receive multiple intra-articular 0.9% Normal saline injections.
|
|
Experimental: NCR100 injection and 0.9% Normal saline
Subjects will receive two injections of 0.9% Normal saline and two injections of NCR100
|
Subjects will receive multiple intra-articular NCR100 injections.
Subjects will receive multiple intra-articular 0.9% Normal saline injections.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dose-Limiting Toxicity(DLT)
Time Frame: 4 weeks after first injection
|
Number of participants with Dose-limiting toxicity in 28 days
|
4 weeks after first injection
|
|
The Western Ontario and McMaster Universities osteoarthritis index(WOMAC)
Time Frame: 48 weeks after first injection
|
Differences of WOMAC scores in changes from baseline between the experimental group and the control group
|
48 weeks after first injection
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Event(AE) or Serious Adverse Event(SAE)
Time Frame: Within 48 weeks of the first infusion
|
Number of participants with treatment-related adverse events or serious adverse events assessed by CTCAE v5.0
|
Within 48 weeks of the first infusion
|
|
Visual analogue scale (VAS)
Time Frame: 8 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks
|
Differences in changes from baseline between experimental groups and the control group.
|
8 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks
|
|
Differences in changes from baseline at 8 weeks, 12 weeks, 24 weeks and 36 weeks of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) between the experimental groups and the control group
Time Frame: 8 weeks, 12 weeks, 24 weeks and 36 weeks
|
WOMAC scores include three subscale scores (pain, stiffness, and physical function)
|
8 weeks, 12 weeks, 24 weeks and 36 weeks
|
|
Differences in changes from baseline to 24 weeks and 48 weeks in cartilages with various regions
Time Frame: 24 weeks and 48 weeks
|
Magnetic resonance imaging (MRI) is used to scan images of knees.
|
24 weeks and 48 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NCR100-1002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.